Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Drug policy 1996]

M Bogaert1

  • 1Heymans Instituut-Vakgroep Farmacologie Universiteit Gent.

Verhandelingen - Koninklijke Academie Voor Geneeskunde Van Belgie
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Regulatory authorities oversee drug development, registration, and post-marketing surveillance. Enhancing rational drug use and evidence-based pharmacotherapy requires a long-term policy, with Belgium needing further development in this area.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence-Based Medicine: A Few Introductory Remarks.

Acta clinica Belgica·2016
Same author

Selected Summaries.

Acta clinica Belgica·2016
Same author

Selected Summaries.

Acta clinica Belgica·2016
Same author

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2015
Same author

Contribution of drug related problems to hospital admission in the elderly.

The journal of nutrition, health & aging·2010
Same author

Buflomedil for intermittent claudication.

The Cochrane database of systematic reviews·2008
Same journal

Air pollution in Belgium: will we be able to comply with the European standards?

Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie·2012
Same journal

The influence of air pollution on health: mechanistic implications.

Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie·2012
Same journal

Air pollution and health--air quality standards.

Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie·2012
Same journal

[Worry about talent in first line health care].

Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie·2012
Same journal

[Piet de Somer, the University of Leuven and the Belgium poliovaccine in 1956-57].

Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie·2012
Same journal

[Emergency guidelines for cosmetic procedures and esthetic skin treatment: recommendations of the medical establishment].

Verhandelingen - Koninklijke Academie voor Geneeskunde van Belgie·2012
See all related articles

Area of Science:

  • Pharmacovigilance and drug regulation
  • Health policy and pharmaceutical management

Context:

  • Regulatory authorities manage drug lifecycle, from clinical trials to post-marketing surveillance.
  • Key responsibilities include drug registration, reimbursement, and ensuring pharmacovigilance.
  • Authorities also play a crucial role in disseminating information to healthcare professionals and patients.

Purpose:

  • To outline the multifaceted roles of regulatory authorities in medication management.
  • To emphasize the importance of post-marketing surveillance for defining product value and reimbursement.
  • To highlight the need for improved prescribing practices and rational drug use.

Summary:

  • Regulatory authorities are responsible for clinical study rules, drug registration, and reimbursement.

Related Experiment Videos

  • Post-marketing activities like pharmacovigilance and drug use studies are vital for assessing product value.
  • Promoting rational drug use and Evidence-Based Medicine requires a long-term policy, an area where Belgium has room for improvement.

    • Impact:

    • Informs policy development for effective medication regulation and management.
    • Supports the implementation of Evidence-Based Medicine and rational pharmacotherapy.
    • Identifies areas for policy enhancement in Belgium to optimize drug utilization and patient outcomes.